PepGen, Inc. (NASDAQ:PEPG) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Key Points

• PepGen has a “Moderate Buy” consensus rating from six analysts, with five buys and one sell; the average 12-month price target is $11.40 versus a recent share price of $2.28.
• Institutional ownership stands at 58.01%, with several hedge funds—including ADAR1 Capital Management and AWM Investment—taking new positions during the second quarter.
• PepGen, a clinical-stage biotechnology company, reported quarterly EPS of -$0.26, beating the consensus estimate of -$0.28; analysts expect full-year EPS of approximately -$1.11.

PepGen, Inc. (NASDAQ:PEPG - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $11.40.

Several equities research analysts have commented on the stock. Craig Hallum started coverage on shares of PepGen in a research note on Tuesday, June 16th. They issued a "buy" rating and a $11.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating on shares of PepGen in a report on Wednesday, September 9th. Wall Street Zen raised PepGen from a "sell" rating to a "hold" rating in a research report on Sunday, June 7th. Finally, Weiss Ratings raised PepGen from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, September 22nd.

Institutional Investors Weigh In On PepGen

A number of hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC boosted its holdings in shares of PepGen by 260.9% in the 2nd quarter. Squarepoint Ops LLC now owns 529,083 shares of the company's stock worth $952,000 after buying an additional 382,487 shares during the last quarter. Artia Global Partners LP purchased a new stake in PepGen during the second quarter worth about $370,000. AWM Investment Company Inc. bought a new stake in PepGen in the second quarter worth about $1,080,000. ADAR1 Capital Management LLC bought a new stake in PepGen in the second quarter worth about $4,664,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in PepGen in the second quarter valued at about $202,000. 58.01% of the stock is currently owned by institutional investors.

PepGen Price Performance

NASDAQ:PEPG opened at $2.28 on Monday. PepGen has a one year low of $1.31 and a one year high of $7.80. The company has a market cap of $157.91 million, a PE ratio of -1.74 and a beta of 2.01. The firm has a 50-day moving average of $2.74 and a 200-day moving average of $2.30.

PepGen (NASDAQ:PEPG - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02. On average, equities research analysts expect that PepGen will post -1.11 earnings per share for the current fiscal year.

About PepGen

PepGen Inc is a clinical-stage biotechnology company developing RNA-based therapeutics for severe neuromuscular and genetic diseases. The company's programs are designed to address conditions caused by genetic mutations by selectively modifying or restoring the production of disease-related proteins.

PepGen's technology platform, Enhanced Delivery Oligonucleotide (EDO), uses peptide-conjugated phosphorodiamidate morpholino oligomers to improve the delivery of therapeutic oligonucleotides into muscle and other tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.